Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
about
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center studyThe diagnosis of idiopathic pulmonary fibrosis: current and future approaches.Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?Recent advances in managing systemic sclerosis.Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice"Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis.Nintedanib for the treatment of idiopathic pulmonary fibrosis.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis.Nintedanib for Idiopathic Pulmonary Fibrosis.What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike!Usual interstitial pneumonia: typical, possible, and "inconsistent" patterns.Idiopathic pulmonary fibrosis: pathogenesis and management.Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis.Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Idiopathic Pulmonary Fibrosis (IPF): An OverviewDiagnosis of Idiopathic Pulmonary Fibrosis in a Possible Usual Interstitial Pneumonia Pattern: a meta-analysisQuantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacityNintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experienceDiagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis
P2860
Q33814559-564A76D0-09F0-4AD0-AF80-4AE94004D847Q33924950-1B1B1C5F-2D86-4DAE-AFCD-7AF3EF718A1EQ38598382-E462FF3E-6C40-4807-A296-A5D1C8D1DDCCQ38759138-42861B5B-F53F-4010-BCD8-3488A78B15D9Q40272697-F3413339-6C87-4DBC-A23E-A0D23775314EQ41151927-3A866E9F-39E6-440C-9189-F7D8E68732B0Q42101627-E1054B57-38AE-4416-AE80-CED451ACA26BQ43482585-01C1FAFB-7C8D-4074-8816-6148F69760F4Q47365093-C091BAD7-3051-4660-99A3-CA0C9296B169Q47658514-11A8AF3A-A438-40D5-B683-737F110C29D8Q47791471-5AED4A77-0F05-42C5-8FDE-34DB38259F0AQ47792568-535500EB-311E-43D0-9D33-E3EEEA999843Q47826077-6312BCF7-53BD-4186-9C6C-17CB4CADADEFQ48003254-1B4CD71E-1032-40F1-A517-1708A59414DDQ48551993-35AB5614-7C27-4DE6-AF4F-B18570679605Q50326794-06B9A337-6D5B-43ED-BD63-9A6D230BE526Q52659380-73E38BEE-97D3-4B47-B0AC-E7C484786A98Q52797163-2227B709-D61A-425B-9872-2E8492945310Q57170607-CBB11598-16D5-4A39-976E-68E20DFC684DQ58116140-FE0E484B-B8EE-4637-9D8C-5F48D70C903FQ58608704-87A7AE86-ED56-44E1-BDA7-461C0F200805Q58698965-05F010BC-8D47-4BEC-9FAB-A761526BF430Q58764186-16BA5D94-8240-45EA-84CB-A6B400D77B45
P2860
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@en
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@nl
type
label
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@en
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@nl
prefLabel
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@en
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@nl
P2093
P2860
P1476
Effect of Nintedanib in Subgro ...... brosis by Diagnostic Criteria.
@en
P2093
Andrew G Nicholson
Athol U Wells
David M Hansell
Florence Le Maulf
Ganesh Raghu
Kevin R Flaherty
Rozsa Schlenker-Herceg
Susanne Stowasser
P2860
P356
10.1164/RCCM.201602-0402OC
P407
P577
2016-06-22T00:00:00Z